Q2 FY26 Results: Profit boosted by one-time Ebix settlement gain

Emphasis Of MatterResults RestatedRelated Party TransactionsExceptional ItemPat Growth 25pctContingent Liabilities IncreasedResults View source PDF

VIKASLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-0.6%1-day move

₹1.65

prior close

₹1.68

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-3.6-1.8-3.6-4.2-0.6-3.0-2.4-3.0-3.6-4.8-7.3-12.1-9.7-20.6

Up moveDown movePending

AI summary

Vikas Lifecare reported H1 FY26 revenue of ₹229.67 cr (up ~3.5% YoY). Net profit surged to ₹124.15 cr from ₹1.99 cr, driven mainly by a one-time ~₹130 cr gain from receiving 51% equity in Ebix International Holdings (UK) via settlement. Q1 FY26 results were restated. Auditor flagged multiple emphasis-of-matter items: pending shareholder approval for related party transactions, pending IGTL share transfer approvals, and unevaluated tax implications of the settlement. Board also approved seeking shareholder consent via postal ballot addendum for RPTs.

Likely market impact

Headline profit masks weak core operations; one-time Ebix gain is not recurring. Auditor flags on RPT approvals, pending compliances, and tax uncertainty warrant caution.